SARS CoV-2 infection among patients using immunomodulatory therapies

Ann Rheum Dis. 2021 Feb;80(2):269-271. doi: 10.1136/annrheumdis-2020-218580. Epub 2020 Aug 5.
No abstract available

Keywords: arthritis; autoimmune diseases; biological therapy; rheumatoid.

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antirheumatic Agents / therapeutic use
  • Arthritis, Rheumatoid / complications
  • Arthritis, Rheumatoid / drug therapy
  • Autoimmune Diseases / complications
  • Autoimmune Diseases / drug therapy*
  • Azithromycin / therapeutic use
  • Biological Products / therapeutic use
  • COVID-19 / complications
  • COVID-19 / mortality
  • COVID-19 / therapy*
  • COVID-19 Drug Treatment
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Glucocorticoids / therapeutic use
  • Hospitalization
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Immunomodulation
  • Immunosuppressive Agents / therapeutic use*
  • Inflammatory Bowel Diseases / complications
  • Inflammatory Bowel Diseases / drug therapy
  • Intensive Care Units
  • Janus Kinase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Respiration, Artificial
  • SARS-CoV-2
  • Sarcoidosis / complications
  • Sarcoidosis / drug therapy
  • Surveys and Questionnaires
  • Tumor Necrosis Factor Inhibitors / therapeutic use
  • Young Adult

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal, Humanized
  • Antirheumatic Agents
  • Biological Products
  • Enzyme Inhibitors
  • Glucocorticoids
  • Immunosuppressive Agents
  • Janus Kinase Inhibitors
  • Tumor Necrosis Factor Inhibitors
  • Hydroxychloroquine
  • Azithromycin
  • tocilizumab